Xilio Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Xilio Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 2.6 times its market value (net cash). Higher than 97% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 2 of the last 3 years; profit grew in 3 of 3. Steadier than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-88.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 80% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-3.7×Operating cash was negative last year, while some debt falls due within a year.
Higher than 61% of Healthcare companies in United States.
Cash Cushion Ratio
2.6× cashCash, after subtracting all debt, is 2.6 times its market value (net cash).
Higher than 97% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Xilio Therapeutics, Inc. made a loss over the last year. Xilio Therapeutics, Inc. owes $0.53 for every $1 it owns. Xilio Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossXilio Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.69The share price is 0.69 times Xilio Therapeutics, Inc.'s book value per share, lower than 86% of Healthcare companies in United States.
Market cap
$50 MThe total market value of all of Xilio Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 73% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$72 MWhat Xilio Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$10.98Net worth divided by the number of shares. The share price of $7.57 is 0.7 times this, which is the P/B above.
Return on equity (ROE)
-55.0%Xilio Therapeutics, Inc. lost 55.0% of its shareholders' money over the last year, lower than 54% of Healthcare companies in United States.
Owes vs Owns
0.53×Xilio Therapeutics, Inc. owes $0.53 for every $1 it owns (moderate), higher than 59% of Healthcare companies in United States.
Dividend yield
NoneXilio Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+590%Revenue rose 590% in the year to Dec 2025.
Profit growth
LossXilio Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-80.1%Xilio Therapeutics, Inc. lost $80 for every $100 of revenue.
Cash vs debt
Net cashXilio Therapeutics, Inc. held $131 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Xilio Therapeutics, Inc.: $50 M ÷ $72 M (30 Jun 2026) = 0.7.
What is Xilio Therapeutics, Inc.'s return on equity?
Xilio Therapeutics, Inc. lost 55.0% of its shareholders' money over the last year, lower than 54% of Healthcare companies in United States.
How much does Xilio Therapeutics, Inc. owe compared with what it owns?
Xilio Therapeutics, Inc. owes $0.53 for every $1 it owns (moderate), higher than 59% of Healthcare companies in United States.
Does Xilio Therapeutics, Inc. pay a dividend?
No. Xilio Therapeutics, Inc. does not currently pay a dividend.
Is Xilio Therapeutics, Inc.'s revenue growing?
Revenue rose 590% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.